XML 42 R27.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Summary of Significant Accounting Policies - Collaborative Research and Licensing Agreements - Revenue Recognition (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | $ 4,448,000 |  |  |  |  |  |  |  | $ 4,448,000 |  |
Revenue recognized | 10,941 | $ 7,090 | $ 13,340 | $ 4,340 | $ 6,440 | $ 7,821 | $ 66,007 | $ 7,252 | 35,711 | $ 87,520 | $ 27,762
Deferred revenue | 94,400 |  |  |  | $ 103,400 |  |  |  | 94,400 | 103,400 |
Development-based |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 827,000 |  |  |  |  |  |  |  | 827,000 |  |
Regulatory-based |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 1,490,000 |  |  |  |  |  |  |  | 1,490,000 |  |
Sales-based |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 2,131,000 |  |  |  |  |  |  |  | 2,131,000 |  |
UNITED STATES |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  | 19,700 | 84,800 | 22,400
Non United States |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  | 16,000 | 2,700 | 5,400
Alexion Pharmaceuticals, Inc. |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 58,000 |  |  |  |  |  |  |  | 58,000 |  |
Revenue recognized |  |  |  |  |  |  |  |  | 1,000 | 6,000 | 8,500
Alexion Pharmaceuticals, Inc. | Regulatory-based |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 28,000 |  |  |  |  |  |  |  | 28,000 |  |
Alexion Pharmaceuticals, Inc. | Sales-based |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 30,000 |  |  |  |  |  |  |  | 30,000 |  |
Amgen, Inc. |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 1,647,500 |  |  |  |  |  |  |  | 1,647,500 |  |
Revenue recognized |  |  |  |  |  |  |  |  | 16,200 | 18,700 | 13,800
Amgen, Inc. | Development-based |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 222,500 |  |  |  |  |  |  |  | 222,500 |  |
Amgen, Inc. | Regulatory-based |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 345,000 |  |  |  |  |  |  |  | 345,000 |  |
Amgen, Inc. | Sales-based |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 1,080,000 |  |  |  |  |  |  |  | 1,080,000 |  |
BI |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 27,000 |  |  |  |  |  |  |  | 27,000 |  |
BI | Development-based |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 9,000 |  |  |  |  |  |  |  | 9,000 |  |
BI | Regulatory-based |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 6,000 |  |  |  |  |  |  |  | 6,000 |  |
BI | Sales-based |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 12,000 |  |  |  |  |  |  |  | 12,000 |  |
CSL Limited |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  | 3,500 |  | 2,500
Janssen |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 10,000 |  |  |  |  |  |  |  | 10,000 |  |
Janssen | Development-based |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 6,000 |  |  |  |  |  |  |  | 6,000 |  |
Janssen | Sales-based |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 4,000 |  |  |  |  |  |  |  | 4,000 |  |
MorphoSys |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 286,500 |  |  |  |  |  |  |  | 286,500 |  |
Revenue recognized |  |  |  |  |  |  |  |  | 12,500 |  |
MorphoSys | Development-based |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 49,500 |  |  |  |  |  |  |  | 49,500 |  |
MorphoSys | Regulatory-based |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 187,000 |  |  |  |  |  |  |  | 187,000 |  |
MorphoSys | Sales-based |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 50,000 |  |  |  |  |  |  |  | 50,000 |  |
Novo Nordisk |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  | 2,700 | 2,900
Novartis |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 2,410,000 |  |  |  |  |  |  |  | 2,410,000 |  |
Revenue recognized |  |  |  |  |  |  |  |  | 2,300 | 59,700 |
Novartis | Development-based |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 540,000 |  |  |  |  |  |  |  | 540,000 |  |
Novartis | Regulatory-based |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 920,000 |  |  |  |  |  |  |  | 920,000 |  |
Novartis | Sales-based |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 950,000 |  |  |  |  |  |  |  | 950,000 |  |
Other |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  | 200 | 400 | 100
2009 Research License and Commercialization Agreement | CSL Limited |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 9,000 |  |  |  |  |  |  |  | 9,000 |  |
Revenue recognized |  |  |  |  |  |  |  |  | 3,500 | $ 0 | $ 2,500
Deferred revenue | 0 |  |  |  |  |  |  |  | 0 |  |
2009 Research License and Commercialization Agreement | CSL Limited | Regulatory-based |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | 4,000 |  |  |  |  |  |  |  | 4,000 |  |
2009 Research License and Commercialization Agreement | CSL Limited | Sales-based |  |  |  |  |  |  |  |  |  |  |
Revenue recognition |  |  |  |  |  |  |  |  |  |  |
Total | $ 5,000 |  |  |  |  |  |  |  | $ 5,000 |  |

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the revenue earned during the period pertaining to collaborations, licenses and milestones. + References No definition available. + Details
Name: | xncr_CollaborationsLicensesAndMilestonesRevenue
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of consideration that will be recognized upon full completion of milestones set forth in a collaborative agreement between two parties. + References No definition available. + Details
Name: | xncr_RevenueRecognitionMilestoneMethodPending
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | xncr_PotentialMilestonesTypeAxis=xncr_DevelopmentBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_PotentialMilestonesTypeAxis=xncr_RegulatoryBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_PotentialMilestonesTypeAxis=xncr_SalesBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=xncr_NonUnitedStatesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_AlexionPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_AmgenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_BIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_CSLLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_JanssenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_MorphoSysMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_NovoNordiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_NovartisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_OtherCustomerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_ResearchLicenseAndCommercialization2009AgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |